AtomVie opens Hamilton radiopharma plant

AtomVie Global Radiopharma has opened a new manufacturing plant in Hamilton, Ontario, adding a large piece of regulated production capacity to a radiopharmaceutical sector where speed, compliance and logistics are tightly linked. The company said on September 4 that the site was purpose-built for clinical and commercial manufacturing and would support customers across development, scale-up and supply. AtomVie describes itself as a contract development and manufacturing organization, or CDMO, focused on radiopharmaceuticals. The new facility is at 10 Aeropark Boulevard in Hamilton. ### Why is this plant more than just another factory? The 72,300-square-foot building matters because radiopharmaceutical manufacturing is not a standard drug-production business. These medicines often involve radioactive isotopes with short usable lives, which means production, quality release and distribution have to work as one system. AtomVie said the Hamilton site was built to expand GMP clinical and commercial manufacturing capacity and to support radiopharmaceutical programs from development through commercial supply. (finance.yahoo.com) Hamilton’s economic development agency said the site is the largest single-site radiopharmaceutical CDMO facility in North America. That claim, while promotional, points to the scale race now under way in the sector as developers try to move radioligand therapies from small clinical batches to repeatable commercial output. ### What, specifically, did AtomVie say it added? (atomvie.com) AtomVie said the facility increases its manufacturing capacity by more than tenfold. Third-party reports carrying the company’s announcement said the project involved more than $160 million of investment. The company’s facility page says the site was designed to expand regulated output for both clinical-stage and commercial-stage programs. The company’s broader pitch is continuity. (investinhamilton.ca) AtomVie says it provides services from early development through commercial manufacturing, and its website says its regulatory team has filed more than 525 submissions to Health Canada and the U.S. Food and Drug Administration. That is the sort of operating detail customers look for in a business where manufacturing know-how and regulatory execution are sold together. ### Why does Hamilton matter for this business? Hamilton already housed AtomVie operations before this opening. (biopharmaapac.com) The company’s earlier expansion materials listed its head office at 10 Aeropark Boulevard and operating activities tied to McMaster University infrastructure in Hamilton. Its corporate history says AtomVie was built on manufacturing and distribution expertise developed through the Center for Probe Development and Commercialization. (atomvie.com) Invest in Hamilton said the new site is expected to create more than 200 highly skilled jobs by the end of 2026. The agency also said AtomVie held its grand opening on September 3, 2026, a timeline that fits with the company’s September 4 announcement and wider pickup in coverage on September 7 and 8. ### What does this say about the radiopharma market right now? Radiopharmaceutical companies have drawn investor and industry attention because approved and experimental products require specialized manufacturing, isotope handling, quality controls and reliable distribution. (atomvie.com) AtomVie’s own materials frame the Hamilton site around “clinical and commercial manufacturing capacity,” which is a concise statement of the bottleneck many developers face as programs advance. AtomVie says its business is to help sponsors move from development into supply. (investinhamilton.ca) In practice, that means the next proof point will not be the ribbon-cutting itself, but how many customer programs the Hamilton plant takes from clinical production into commercial-scale manufacturing over the coming quarters. (atomvie.com 1) (atomvie.com 2)